hrs4r
 I want to donate
Firma
GARY ÁLVAREZ-BRAVO
Position
Investigador/a Pre-doctoral – R1
Predoctoral Researchers – R1

Projectes

Codi oficial: RD21/0002/0063 - EM Start date:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ, GARY CICERÓN ÁLVAREZ BRAVO Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: Estudio de biomarcadores moleculares neurodegeneración Start date:01/01/2022 Data fi: 31/12/2024 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ, GARY CICERÓN ÁLVAREZ BRAVO Organisme finançador: FRANCISCO SORIA MELGUIZO, S.A
Codi oficial: HZ16YWZ3K Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ, GARY CICERÓN ÁLVAREZ BRAVO Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA (AGAUR)
Codi oficial: PI23/00517 Start date:01/01/2024 Data fi: 31/12/2026 Investigador/a principal: ANNA QUIROGA VARELA, LLUÍS RAMIÓ TORRENTÀ Organisme finançador: INSTITUTO DE SALUD CARLOS III
Codi oficial: COGNIPROG Start date:01/09/2023 Data fi: 31/08/2024 Investigador/a principal: LLUÍS RAMIÓ TORRENTÀ, GARY CICERÓN ÁLVAREZ BRAVO Organisme finançador: ASOCIACIÓN ESCLEROSIS MULTIPLE ESPAÑA (AEDEM)

Publicacions

Gich J, Salavedra-Pont J, Coll-Martinez C, Quintana E, Álvarez-Bravo G, Robles-Cedeño R, Buxó M, Contreras-Rodriguez O, Ramió-Torrentà L

The nature of memory impairment in multiple sclerosis: understanding different patterns over the course of the disease

Frontiers in Psychology, 2024, 14, 1269794-1269794 dx.doi.org/10.3389/fpsyg.2023.1269794
Muñoz-San Martín M, Gómez I, Quiroga-Varela A, Gonzalez-Del Río M, Robles Cedeño R, Álvarez G, Buxó M, Miguela A, Villar LM, Castillo-Villalba J, Casanova B, Quintana E, Ramió-Torrentà L

miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 dx.doi.org/10.1212/NXI.0000000000200069
Schneider SA, Desai S, Phokaewvarangkul O, Rosca EC, Sringean J, Anand P, Bravo GÁ, Cardoso F, Cervantes-Arslanian AM, Chovatiya H, Crosiers D, Dijkstra F, Fearon C, Grandas F, Guedj E, Méndez-Guerrero A, Hassan M, Jankovic J, Lang AE, Makhoul K, Muccioli L, O'Shea SA, Ostovan VR, Perez-Sanchez JR, Ramdhani R, Ros-Castelló V, Schulte C, Shah P, Wojtecki L, Pal PK

COVID19-associated new-onset movement disorders: a follow-up study.

JOURNAL OF NEUROLOGY, 2023, 270, 1-7 dx.doi.org/10.1007/s00415-023-11661-x
Puig-Casadevall M, Álvarez-Bravo G, Varela AQ, Robles-Cedeño R, Sànchez Cirera L, Miguela A, Laguillo G, Montalban X, Hauser SL, Ramió-Torrentà L

Progressive multifocal leukoencephalopathy in a patient with relapsing multiple sclerosis treated with ocrelizumab: A case report.

EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30, 3357-3361 dx.doi.org/10.1111/ene.15988
Coll-Martinez C, Salavedra-Pont J, Buxó M, Quintana E, Quiroga-Varela A, Robles-Cedeño R, Puig M, Álvarez-Bravo G, Ramió-Torrentà L, Gich J

Differences in metacognition between multiple sclerosis phenotypes: cognitive impairment and fatigue are key factors.

Frontiers in Psychology, 2023, 14, 1163112-1163112 dx.doi.org/10.3389/fpsyg.2023.1163112
Álvarez-Bravo G

A new phenotype of myorhythmia: Oculofacial myorhythmia in a patient with Erdheim Chester disease.

PARKINSONISM & RELATED DISORDERS, 2023, 116, 105889-105889 dx.doi.org/10.1016/j.parkreldis.2023.105889
López-Domínguez D, Álvarez-Bravo G, Puig-Casadevall M

Reversible hyperintensity in middle cerebellar peduncles. An infrequent finding in Marchiafava-Bignami disease.

REVISTA DE NEUROLOGIA, 2023, 77, 227-228 dx.doi.org/10.33588/rn.7709.2023119
Ferrer Tarrés R, Garcia Huguet M, Vera Cáceres C, Boix Lago A, Ramió Torrentà L, Álvarez-Bravo G

Iatrogenic Shapiro syndrome: a case report.

NEUROLOGICAL SCIENCES, 2023, 45, 1267-1270 dx.doi.org/10.1007/s10072-023-07263-0
Álvarez Bravo G, Sánchez Cirera L, Angerri Nadal M, Ramió I Torrentà L

Clinical heterogeneity in patients with myoclonus associated to COVID-19

NEUROLOGICAL SCIENCES, 2022, 43, 1587-1592 dx.doi.org/10.1007/s10072-021-05802-1
Zabalza A, Arrambide G, Otero-Romero S, Pappolla A, Tagliani P, López-Maza S, Cárdenas-Robledo S, Esperalba J, Fernández-Naval C, Martínez-Gallo M, Castillo M, Bonastre M, Resina-Salles M, Bertran J, Rodriguez-Barranco M, Carbonell-Mirabent P, Gonzalez M, Merchan M, Quiroga-Varela A, Miguela A, Gómez I, Álvarez G, Robles R, Perez Del Campo D, Queralt X, Soler MJ, Agraz I, Martinez-Valle F, Rodríguez-Acevedo B, Midaglia L, Vidal-Jordana Á, Cobo-Calvo Á, Tur C, Galan I, Castillo J, Río J, Espejo C, Comabella M, Nos C, Sastre-Garriga J, Ramió-Torrentà L, Tintoré M, Montalban X

Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?

MULTIPLE SCLEROSIS JOURNAL, 2022, 28, 1138-1145 dx.doi.org/10.1177/13524585221089540

Formulari de contacte

About IDIBGI!

menu